The UK has introduced significant amendments to its clinical trial legislation to further accelerate trial set-up and enhance the UK's appeal as a research destination. The changes to the UK Clinical Trial Regulations (UK CTR), which take effect from 28 April 2026, include:

• Faster approvals: A single Integrated Research Application System (IRAS) application enables joint MHRA and Research Ethics Committee (REC) review, with a maximum 30-day decision timeline, and only 14 days for Phase I healthy volunteer trials.
• Notifiable trials: Low-intervention trials will only require notification (not full MHRA approval), accelerating start-ups and reducing regulatory burden. Around 20% of studies – particularly lower-risk trials – are expected to move to this fast-track notification process.
• Decentralized manufacturing: New provisions (already in effect) allow for modular and point-of-care manufacturing, supporting innovation and flexibility in trial delivery.
• Transparency and accountability: Mandatory public registry publication, participant summaries, and simplified consent and labeling requirements make compliance easier and enhance public trust.

These regulatory reforms not only align the UK with international standards, but, in many respects, go further, offering shorter timelines and reduced administrative hurdles compared to the EU. The changes are supported by a national network of 21 Commercial Research Delivery Centers, coordinated efforts from the MHRA and Health Research Authority (HRA), and ongoing guidance for sponsors and investigators. Additionally, the standardized UK trial contracting process and adoption of a National Contract Value Review (NCVR) has already reduced negotiation times by over a third, further supporting efficient trial setup.

Clinical trial applications rose by 9% between January and November 2025 compared to the same period in 2024 (according to the MHRA), and by 35% in 2024 compared to 2023. This growth was especially pronounced in early-phase and innovative research.

Engagement with regulators is also on the rise, with MHRA scientific advice meetings increasing by 75% in 2025. This reflects a growing trend of companies seeking early input to optimize trial design and avoid costly delays.

Central to this momentum is the UK Government's 2025 Life Sciences Sector Plan, which aims to position the UK as the world's third most attractive destination for clinical trials by 2035, behind only the U.S. and China. A key ambition is to reduce clinical trial setup time to only 150 days by March 2026. The MHRA's performance is already notable, with 99% of clinical trial applications reviewed on time, and most completed ahead of target, underscoring the UK's commitment to deliver large-scale, high-quality clinical research.